<DOC>
	<DOCNO>NCT01220141</DOCNO>
	<brief_summary>This study conduct Europe Asia . The aim observational study monitor antibody formation towards room temperature stable formulation NovoSeven® ( activate recombinant human factor VII ) .</brief_summary>
	<brief_title>Observational Study Safety Room Temperature Stable NovoSeven® Patients With Haemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed congenital haemophilia A B inhibitor factor VIII factor IX Treated room temperature stable NovoSeven®</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>